key: cord-0859210-z43p1dmf
authors: Li, Fei‐Ka; An, De‐Wei; Guo, Qian‐Hui; Zhang, Yi‐Qing; Qian, Jia‐Ye; Hu, Wei‐Guo; Li, Yan; Wang, Ji‐Guang
title: Day‐by‐day blood pressure variability in hospitalized patients with COVID‐19
date: 2021-07-31
journal: J Clin Hypertens (Greenwich)
DOI: 10.1111/jch.14338
sha: 751f7b235ba9833472505d28aeee9a3a296da240
doc_id: 859210
cord_uid: z43p1dmf

In a retrospective analysis, the authors investigated day‐by‐day blood pressure variability (BPV) and its association with clinical outcomes (critical vs. severe and discharged) in hospitalized patients with COVID‐19. The study participants were hospitalized in Tongji Hospital, Guanggu Branch, Wuhan, China, between February 1 and April 1, 2020. BPV was assessed as standard derivation (SD), coefficient of variation (CV), and variability independent of mean (VIM). The 79 participants included 60 (75.9%) severe patients discharged from the hospital after up to 47 days of hospitalization, and 19 (24.1%) critically ill patients transferred to other hospitals for further treatment (n = 13), admitted to ICU (n = 3) or died (n=3). Despite similar use of antihypertensive medication (47.4% vs. 41.7%) and mean levels of systolic/diastolic blood pressure (131.3/75.2 vs. 125.4/77.3 mmHg), critically ill patients, compared with severe and discharged patients, had a significantly (p ≤ .04) greater variability of systolic (SD 14.92 vs. 10.84 mmHg, CV 11.39% vs. 8.56%, and VIM 15.15 vs. 10.75 units) and diastolic blood pressure (SD 9.38 vs. 7.50 mmHg, CV 12.66% vs. 9.80%, and VIM 9.33 vs. 7.50 units). After adjustment for confounding factors, the odds ratios for critical versus severe and discharged patients for systolic BPV were 3.41 (95% confidence interval [CI] 1.20‐9.66, p = .02), 4.09 (95% CI 1.14‐14.67, p = .03), and 2.81 (95% CI 1.12‐7.05, p = .03) for each 5‐mmHg increment in SD, 5% increment in CV, and 5‐unit increment in VIM, respectively. Similar trends were observed for diastolic BPV indices (p ≤ .08). In conclusion, in patients with COVID‐19, BPV was greater and associated with worse clinical outcomes.

The SARS-COV-2 (COVID-19) pandemic is still ongoing worldwide.

Early studies repeatedly showed that, in the presence of hypertension, the disease of COVID-19 was more severe and associated with a higher fatality. 1 Because angiotensin converting enzyme (ACE) 2 behaves as a mediator of the COVID-19 infection, early views focused on the use of ACE inhibitors or angiotensin receptor blockers that may potentially increase the expression of ACE2 in several tissues, though not necessarily the lungs. 2 Most studies on this topic did not show any significant association. 3, 4 The results of subsequent studies suggested that hypertension itself and its target organ damage and complications might be the cause of high risk and fatality. 5 We hypothesize that blood pressure fluctuates on critical conditions, such as COVID-19, and increases the severity and fatality of the disease. There is some evidence on the negative health consequences of the day-by-day blood pressure variability (BPV) during hospitalization on critical disease conditions. 6 In the present study, we investigated the day-by-day clinic BPV and its association with clinical outcomes in hospitalized patients with COVID-19.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

The study participants were hospitalized patients with COVID-19 in During the whole study period, a total of 90 patients were hospitalized. In this retrospective analysis, we attempted to include as many patients as possible. We did not apply any exclusion criteria except for the minimum required number of blood pressure readings for the computation of BPV indices. We had to exclude 11 patients with less than three blood pressure readings obtained during the whole hospitalization period. Thus, the present analysis included 79 patients.

Blood pressure was measured in the morning usually at 06:00-10:00 in the supine position by a doctor or nurse using a validated electronic blood pressure monitor (Omron J30, an equivalence of HEM-7130 in the China market, Omron Healthcare, Kyoto, Japan) 8 before breakfast and intake of antihypertensive drugs. One reading was obtained on each occasion. Mean arterial pressure was calculated as the sum of a third of systolic blood pressure plus two thirds of diastolic blood pressure.

Information on other clinical, anthropometric, and biochemical measurements was also collected from the medical records. Body height and body weight were self-reported. Body mass index was calculated as the body weight in kilograms divided by the body height in meters squared. Estimated glomerular filtration rate (eGFR) was calculated by the use of the CKD-EPI formula. 9

Information on the diagnosis, symptoms, disease severity, treatment, and clinical outcomes of COVID-19 was collected from medical records. Oxygen saturation was measured with pulse oximetry.

Hypoxia was defined as an oxygen saturation of ≤93%. 7 Adverse clinical outcomes included transfer to other hospitals for further treatment, ICU admission or death due to COVID-19 exacerbation. Patients were discharged at doctor's discretion when the discharge requirements were met, including (1) normothermia, (2) significant recovery of respiratory symptoms, (3) significant improvement of acute diffusive lesion of the lung identified by imaging, and (4) two consecutive negative results of COVID-19 nucleic acid testing within an interval of at least one day. Patients were classified as "severe" if discharged and "critical" if transferred to other hospitals for further treatment, admitted to ICU, or died. Values are mean ± SD, median (interquartile range) or number of patients (% of column total). Abbreviations: eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; LDL, low density lipoprotein.

The 79 study participants included 60 (75.9%) severe patients discharged from the hospital after up to 47 days of hospitalization, and 19 (24.1%) critically ill patients transferred to other hospitals for further treatment (n = 13, 16.5%), admitted to ICU (n = 3, 3.8%), or died (n = 3, 3.8%). The duration of blood pressure measurement was 3-47 days (median 18 days). During follow-up, blood pressure was measured every day in 15 (19.0%), at least every other day in 41 (51.9%), and even less frequently in 23 (29.1%) patients. Table 2 

In a logistic regression model, we included age and sex and the confounding factors with a significant between-group difference identified in Tables 1 and 2 Values are mean ± standard deviation (SD) or number of patients (% of column total), unless indicated otherwise. Abbreviations: COVID-19, coronavirus disease 2019; CV, coefficient of variation.

Day-by-day clinic blood pressure variability of standard deviation (A), coefficient of variation (B), and variability independent of mean (C) by clinical outcome. Symbols represent mean values in severe (dots) and critically ill (squares) patients, adjusted for age, sex, and the mean level of systolic and diastolic blood pressure and pulse rate, and presence of hypoxia during treatment. p values for the comparison between severe and critically ill patients are given 

The key finding of the present study was that the critically ill patients had increased systolic and diastolic BPV, which was associated with reported that higher mean arterial pressure variability was associated with a higher risk of mortality as outcome and with older age, higher C reactive protein concentration, and markers of cardiac and renal injury as the related risk factors. 14 However, it is also possible that the disrupted blood pressure regulation or the too high or too low blood pres-sure as indicated by increased BPV directly caused worse clinical outcomes, such as shock.

The study should be interpreted within the context of its limitations.

The sample size was rather small and hence inadequately powered, but nevertheless allowed detection of significant associations between BPV and clinical outcomes. In addition, for the sake of minimum intervention, only one blood pressure reading was obtained on each measurement occasion. However, blood pressure was measured for the whole study period.

In conclusion, in hospitalized patients with COVID-19, day-by-day clinic BPV was higher and associated with worse clinical outcomes.

The finding pinpoints the importance of blood pressure monitoring and further investigation for the underlying causes of increased BPV in patients with COVID-19.

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Coronaviruses and the cardiovascular system: acute and long-term implications

Association of use of angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19)

Reninangiotensin-aldosterone system blockers and the risk of COVID-19

Prevalence of diabetes and hypertension and their associated risks for poor outcomes in COVID-19 patients

In-hospital day-by-day systolic blood pressure variability during rehabilitation: a marker of adverse outcome in secondary prevention after myocardial revascularization

Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 6)

Validation of three automatic devices for the self-measurement of blood pressure according to the European Society of Hypertension International Protocol revision 2010: the Omron HEM-7130, HEM-7320F, and HEM-7500F

CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate

Association of cardiovascular disease and 10 other pre-existing comorbidities with covid-19 mortality: a systematic review and meta-analysis

Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use and COVID-19 infection among 824 650 patients with hypertension from a US integrated healthcare system

Extrapulmonary manifestations of COVID-19

Clinical impact of blood pressure variability in patients with COVID-19 and hypertension. Blood Press Monit. 2021. EPub Ahead of Print. How to cite this article

Day-by-day blood pressure variability in hospitalized patients with COVID-19